Cuatrecasas advised Partners Group, a leading global private markets firm acting on behalf of its clients, on acquiring a majority stake in FairJourney Biologics from GHO Capital Partners.

Founded in 2012 and based in Porto, FairJourney Biologics is a Portuguese biotechnology company and contract research organization (CRO) that specializes in assisting pharmaceutical and biotechnology firms with developing next-generation antibody-based therapies. The company offers services in antibody discovery, engineering, production, and characterization. Through its established partnerships, FairJourney Biologics has contributed to the active clinical development of 14 therapies aimed at treating patient needs in oncology, immunology and cardiovascular diseases.

The Cuatrecasas team, comprising lawyers from multiple practice areas, was led by M&A and private equity lawyers Mariana Norton dos Reis and Francisco Martins Caetano. Joining them were Joana Silveira Botelho and Luís Ribeiro Telles, lawyers from the Life Sciences and Healthcare Practice Area; and Manuel Requicha Ferreira, lawyer from the Finance Practice Area. The team also included lawyers from other practice areas, such as Intellectual Property, Public Law and Labor.

Cuatrecasas worked with Ropes & Gray on this transaction.

Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Suma Capital strengthens Gestcompost to ...

by Suma Capital

Since Suma Capital’s entry in 2020, Gestcompost has quadrupled its E...

Photos Stream